# Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

> **NCT07078591** · PHASE2 · RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Daunorubicin
- **DRUG:** Idarubicin（IDA）
- **DRUG:** Cytarabine (Ara-C)
- **BIOLOGICAL:** GPBMC infusion

## Key facts

- **NCT ID:** NCT07078591
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2030-06
- **Final completion:** 2031-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07078591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07078591, "Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07078591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*